MX2018013354A - Terapia de combinacion para tratamiento de cancer. - Google Patents

Terapia de combinacion para tratamiento de cancer.

Info

Publication number
MX2018013354A
MX2018013354A MX2018013354A MX2018013354A MX2018013354A MX 2018013354 A MX2018013354 A MX 2018013354A MX 2018013354 A MX2018013354 A MX 2018013354A MX 2018013354 A MX2018013354 A MX 2018013354A MX 2018013354 A MX2018013354 A MX 2018013354A
Authority
MX
Mexico
Prior art keywords
combination therapy
cancer treatment
cancer
subject
administering
Prior art date
Application number
MX2018013354A
Other languages
English (en)
Inventor
L Keene Jeffery
P Riley Dennis
A Beardsley Robert
R Spitz Douglas Jr
A Fath Melissa
Original Assignee
Galera Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs Llc filed Critical Galera Labs Llc
Publication of MX2018013354A publication Critical patent/MX2018013354A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un método para tratar el cáncer en un sujeto incluye administrar al menos un agente activo que incluye uno o más de un inhibidor de tiorredoxina reductasa y un agente de agotamiento de glutatión, y administrar un complejo de anillo macrocíclico pentaaza correspondiente a la fórmula (I) a continuación. (ver Fórmula).
MX2018013354A 2016-05-03 2017-05-03 Terapia de combinacion para tratamiento de cancer. MX2018013354A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331253P 2016-05-03 2016-05-03
PCT/US2017/030871 WO2017192740A2 (en) 2016-05-03 2017-05-03 Combination therapy for cancer treatment

Publications (1)

Publication Number Publication Date
MX2018013354A true MX2018013354A (es) 2019-02-20

Family

ID=60203338

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013354A MX2018013354A (es) 2016-05-03 2017-05-03 Terapia de combinacion para tratamiento de cancer.

Country Status (14)

Country Link
US (1) US20190151331A1 (es)
EP (1) EP3452060A4 (es)
JP (2) JP2019514962A (es)
KR (2) KR20180132939A (es)
CN (1) CN109414454A (es)
AU (2) AU2017260425B2 (es)
BR (1) BR112018072560A2 (es)
CA (1) CA3022699A1 (es)
CL (1) CL2018003123A1 (es)
EA (1) EA201892510A3 (es)
IL (3) IL300085A (es)
MX (1) MX2018013354A (es)
SG (2) SG11201809606YA (es)
WO (1) WO2017192740A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056675B1 (en) 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
US9149483B2 (en) 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
DK3334744T3 (da) 2015-08-11 2020-07-27 Galera Labs Llc Makrocykliske pentaaza-ringkomplekser med oral biotilgængelighed
RS61012B1 (sr) 2016-05-03 2020-11-30 Bayer Pharma AG Aromatični derivati sulfonamida
CN109906081A (zh) 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
JP7388702B2 (ja) * 2017-11-15 2023-11-29 学校法人藤田学園 抗腫瘍剤及び配合剤
US20200397817A1 (en) * 2017-11-30 2020-12-24 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
GB201800733D0 (en) * 2018-01-17 2018-02-28 Cambridge Entpr Ltd Cancer
CA3090129A1 (en) * 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
JP2019131508A (ja) * 2018-01-31 2019-08-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
WO2019232648A1 (en) * 2018-06-08 2019-12-12 Atomic Energy Of Canada Limited / Énergie Atomique Du Canada Limitée Use of a checkpoint inhibitor in combination with ultralow dose whole body irradiation
CN109620836B (zh) * 2018-12-24 2021-05-18 陕西科技大学 一种具有抗乳腺癌作用的复方药物组合物及其用途和基于此组合物的药物
WO2021050490A1 (en) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
JP2022551494A (ja) * 2019-10-10 2022-12-09 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー マンガン含有配位錯体の水性製剤の製造方法、製剤および処置方法
EP4157242A1 (en) * 2020-06-02 2023-04-05 Galera Labs, LLC Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
WO2022026753A1 (en) * 2020-07-29 2022-02-03 University Of Kentucky Research Foundation Gold(iii) compounds and cancer cell-selective modulation of mitochondrial respiration and metabolism
WO2024026273A1 (en) * 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724550C (en) * 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
ES2600789T3 (es) * 2008-10-29 2017-02-10 Istituto Superiore di Sanità Tratamiento de infecciones por VIH-1 latentes usando auranofina o trióxido de arsénico
US9149483B2 (en) * 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases

Also Published As

Publication number Publication date
CA3022699A1 (en) 2017-11-09
SG10202106462TA (en) 2021-07-29
WO2017192740A2 (en) 2017-11-09
KR20180132939A (ko) 2018-12-12
IL262661B (en) 2022-03-01
IL300085A (en) 2023-03-01
AU2017260425A1 (en) 2018-11-22
SG11201809606YA (en) 2018-11-29
KR20230075528A (ko) 2023-05-31
BR112018072560A2 (pt) 2019-02-19
EA201892510A3 (ru) 2019-09-30
CN109414454A (zh) 2019-03-01
US20190151331A1 (en) 2019-05-23
AU2017260425B2 (en) 2023-04-06
IL262661A (en) 2018-12-31
EA201892510A2 (ru) 2019-06-28
JP2023036950A (ja) 2023-03-14
JP2019514962A (ja) 2019-06-06
IL290149A (en) 2022-03-01
AU2023204318A1 (en) 2023-07-27
EP3452060A2 (en) 2019-03-13
EP3452060A4 (en) 2020-01-01
CL2018003123A1 (es) 2019-05-03

Similar Documents

Publication Publication Date Title
MX2018013354A (es) Terapia de combinacion para tratamiento de cancer.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2022008868A (es) Tratamiento del cancer con tg02.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2017015896A (es) Agente anticancerigeno.
MX2016002857A (es) Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2019012465A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2017004580A (es) Combinaciones de auristatina sinergica.
MX2022001004A (es) Inhibidores de enzimas.
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2019013862A (es) Terapia de combinacion.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY